cyc 202 has been researched along with nsc 65346 in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (nsc 65346) | Trials (nsc 65346) | Recent Studies (post-2010) (nsc 65346) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 82 | 0 | 15 |
| Protein | Taxonomy | cyc 202 (IC50) | nsc 65346 (IC50) |
|---|---|---|---|
| Adenosine kinase | Homo sapiens (human) | 0.47 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cappellini, A; Chiarini, F; Martelli, AM; McCubrey, JA; Ognibene, A | 1 |
1 other study(ies) available for cyc 202 and nsc 65346
| Article | Year |
|---|---|
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Nucleosides; Purines; Pyrimidine Nucleosides; RNA, Messenger; Roscovitine | 2009 |